

DAFTAR PUSTAKA

- Departemen Agama RI. 2011. *Al-Qur'an dan Terjemahnya*. Bandung: PT. Sygma Examedia Arkanlee
- AmericanPsychiatric Association. 1994. *Diagnostic and Statistical Manual of Mental Disorders (4th Ed.)*. Washington DC: AmericanPsychiatric Association
- Asmaran. 1992. *Pengantar Studi Akhlak*. Jakarta: Rajawali Press, hal:2
- Atkinson, R.L.,Atkinson, R.C., Hilgard, E.R. 2008. *Pengantar Psikologi, Edisi Delapan*. Jakarta: Erlangga.
- Azhrudin, Hasanuddin. 2004. *Pengantar Studi Al Akhlak*. Jakarta: Raja Grafindo Persada, hal: 4
- Baumann M H, Clark R D, Budzynski A G, Partilla J S, Blough B E, Rothman R B. 2005. *N-substituted Piperazines Abused by Humans Mimic The Molecular Mechanism of 3,4 methylenedioxymethamphetamine (MDMA, or 'Ecstasy')*. *Neuropsychopharmacology* 30: 550–560
- Bogatcheva E, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J Barbosa F, Einck L, Nacy C A, Protopopova M. 2006. *Identification of New Diamine Scaffolds with Activity against Mycobacterium tuberculosis*. *J Med Chem* 49: 3045–3048
- Bye C, Munro-Faure A D, Peck A W, Young P A. 1973. *A Comparison of The Effects of 1-benzylpiperazine and Dexamphetamine on Human Performance Tests*. *Eur J Clin Pharmacol* 6: 163–169
- Cabulea L. 2006. *Sensitivity Analysis of Cost in a Transportation Problem, International Convergence on Theory and Application of Mathematics and Informatics ICTMSI 2005*. Alba Iulia, Romania
- Campbell H, Cline W, Evans M, Lloyd J, Peck A W. 1973. *Comparison of The Effects of Dexamphetamine and 1-Benzylpiperazine in Former Addicts*. *Eur J Clin Pharmacol* 6: 170–176
- De Boer D, Bosman I J, Hidvegi E, Manzoni C, Benko A A, dos Reys L J, Maes R A. 2001. *Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market*. *Forensic Sci Int* 121: 47–56
- Depag RI. 2002. *Aqidah Akhlak*. Jakarta: Direktorat Jendral Kelembagaan Islam, hal: 59

- Fantegrossi W E, G Winger, J H Woods, W L Woolverton, A Coop. 2005. *Reinforcing and Discriminative Stimulus Effects of 1-Benzylpiperazine and Trifluoromethylphenylpiperazine in Rhesus Monkeys*. Drug Alcohol Depend 77: 161–168
- Fonyo M, A Guttman, K Magyar. 1987. *Species Differences In The In Vitro Metabolism Of EGYT-475, A New Antidepressant Agent*. Pol J Pharmacol Pharm 39: 129–134
- Guttman A, J Nagy, K Magyar. 1987. *The Metabolism Of EGYT-475, a New Antidepressant Agent, In Rats*. Pol J Pharmacol Pharm 39: 123–128
- Guyton A C. Hall J E. 1997. *Buku Ajar Fisiologi Kedokteran*. Edisi 9. Jakarta : EGC. P. 208 – 212, 219 – 223, 277 – 282, 285 – 287.
- Hakim A A, Jaih Mubarak. *Metodologi Studi Islam*. Bandung: Rosda Karya, 2007, hal.: 200
- Hakim M L. 2005. *Raudhah Taman Jiwa Kaum Sufi*. Risalah Gusti, hal:186
- Hamzah Y. 10983. *Etika Islam*. Bandung: Diponegoro, hal: 62
- Johnstone Alice C, Rod A Lea, Katie A Brennan, Susan Schenk, Martin A Kennedy, Paul S Fitzmaurice. 2007. *Benzylpiperazine: a Drug of Abuse?*. Journal of Psychopharmacology 21: 888-894
- Kosoczky I, Grasser K, Kiszelly E, Toncsev E, Petocz L. 1978. *The Antidepressant Activity Of A New Piridin-Carbonic Acid Derivative, EGYT-475*. 7th International Congress of Pharmacology. Pergamon Press, Paris Abstract No 486
- Lawrence Green. 1980. *Health Education Planning, a Diagnostic Approach*. California: Mayfield Publishing
- Magyar K. 1987. *Pharmacokinetic Aspects of The Mode of Action of EGYT- 475, a New Antidepressant Agent*. Pol J Pharmacol Pharm 39: 107–112
- Mahjuddin. 1991. *Akhlak Tasawuf*. Jakarta: Kalam Mulia, hal:3
- Malamud W, Hoagland, H. & Kaufman, I. C. 1946. *A new psychiatric rating scale*. Psychosom. Med. 8: 243-245
- Mansur, Ahmad A M S. dkk. 2009. *Perilaku Manusia dalam Pandangan Islam dan Ilmu Psikologi Modern, Terj. Bambang Suryadi*. Jakarta: Mitsaq Pustaka

- Meririnne E, M Kajos, A Kankaanpaa, T Seppala. 2006. *Rewarding Properties of 1-Benzylpiperazine, a New Drug Of Abuse, In Rats*. Basic Clin Pharmacol Toxicol 98: 346–350
- Mukhsin KA. 2007. *Narkoba dan Permasalahannya*. Yogyakarta: Dinas Pendidikan Pemerintahan Provinsi Yogyakarta
- Nasution H. 1979. *Islam Ditinjau Dari Berbagai Aspeknya*. Jakarta: UI Press
- National Institute of Drug Abuse. 2014. *DrugFacts: Methamphetamine*. <http://www.drugabuse.gov/publications/drugfacts/methamphetamine>. Diakses: 22 Agustus 2017
- Notoatmodjo S. 2003. *Pendidikan dan Perilaku Kesehatan / Oleh Soekidjo Notoatmodjo*. Jakarta: Rineka Cipta
- Oberlander C, C Euvrard, C Dumont, J R Boissier. 1979. *Circling Behavior Induced by Dopamine Releasers and/or Uptake Inhibitors During Degeneration Of The Nigrostriatal Pathway*. 60: 163–170
- Price Sylvia. A Lorraine, M Wilson. 1995. *Buku 1 Patofisiologi “Konsep Klinis Proses-Proses Penyakit”*, edisi : 4. Jakarta : EGC.
- Qardhawi Y. 1993. *Halal dan Haram dalam Islam*. Jakarta: PT. Bina Ilmu
- Rotzinger S, J Fang, R T Coutts, G B Baker. 1998. *Human CYP2D6 and Metabolism of M-Chlorophenylpiperazine*. Biol Psychiatry 44: 1185–1191
- Sheridan Janie L and Butler Rachael A. 2007. *Highs And Lows: Patterns of Use, Positive and Negative Effects of Benzylpiperazine-Containing Party Pills (BZP-Party Pills) Amongst Young People In New Zealand*. Harm Reduction Journal 4: 1-10
- Staack R F, G Fritschi, H H Maurer. 2002. *Studies On The Metabolism And Toxicological Detection Of The New Designer Drug N-Benzylpiperazine In Urine Using Gas Chromatography-Mass Spectrometry*. J Chromatogr B Analyt Technol Biomed Life Sci 773: 35–46
- Staack R F, L D Paul, D Springer, T Kraemer, H H Maurer. 2004a. *Cytochrome P450 Dependent Metabolism of The New Designer Drug 1-(3-Trifluoromethylphenyl)Piperazine (TFMPP). In Vivo Studies in Wistar and Dark Agouti Rats As Well As In Vitro Studies in Human Liver Microsomes*. Biochem Pharmacol 67: 235–244
- Staack R F, D S Theobald, L D Paul, D Springer, T Kraemer, H H Maurer. 2004b. *In Vivo Metabolism of The New Designer Drug 1-(4-*

Methoxyphenyl)Piperazine (Meopp) in Rat and Identification of The Human Cytochrome P450 Enzymes Responsible For The Major Metabolic Step. Xenobiotica 34: 179–192

STANZ. 2005. *Submission of Social Tonics Association of New Zealand to the Health Select Committee on the matter of Misuse of Drugs Amendment Bill (No 3) and the Supplementary Order Paper.* <http://www.stanz.org.m/SOP%20Submission%20for%20STANZ%20%20Jan%2020052.pdf>. Diakses 22 Agustus 2017.

Syafii A. 2009. *Penyalahgunaan Narkoba Dalam Perspektif Hukum Positif dan Hukum Islam.* Jurnal Hunafa 6: 219-232

Tekes K, L Tothfalusi, B Malomvolgyi, F Herman, K Magyar. 1987. *Studies on The Biochemical Mode of Action of EGYT-475, a New Antidepressant.* Pol J Pharmacol Pharm 39: 203–211

Tri M. 2003. *Kumpulan Fatwa Mengenai Ganja.* Fatawa V

Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, Inoue H, Kishi T, Tsuchihashi H. 2006. *Metabolism and The Urinary Excretion Profile Of The Recently Scheduled Designer Drug N-Benzylpiperazine (BZP) In The Rat.* J Anal Toxicol 30: 38–43

Vollenweider F X, A Gamma, Liechti M, Huber T. 1998. *Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers.* Neuropsychopharmacology 19: 241–251

Wilkins C, M Girling, P Sweetsur, T Huckle, J Huakau. 2006. *Legal party pill use in New Zealand: Prevalence of use, availability, health harms and ‘gateway effects’ of benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP).* Centre for Social and Health Outcomes Research and Evaluation (SHORE). Massey University, Auckland, New Zealand

ECCD. 2014. *N-Benzylpiperazine (BZP).* World Health Organization, 36th.

Zainuddin A, Jamhari M. 1999. *AllIslam 2: Muamalah dan Akhlak.* Bandung: Pustaka Setia, hal.: 78.